Comera Life Sciences Holdings, Inc. (CMRA)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 633.1 Thousand | 319.83 Thousand | 442.91 Thousand |
| Cost of Revenue | 210.39 Thousand | 161 Thousand | 104.4 Thousand |
| Gross Profit | 422.71 Thousand | 158.82 Thousand | 338.51 Thousand |
| Operating Expenses | 12.39 Million | 5.69 Million | 2.46 Million |
| Selling, General and Administrative Expenses | 10.65 Million | 3.94 Million | 1.2 Million |
| Research and Development Expenses | 1.73 Million | 1.75 Million | 1.26 Million |
| Other Expenses | - | -76.73 Thousand | 2033.00 |
| Cost and Expenses | 12.6 Million | 5.85 Million | 2.57 Million |
| Operating Income | -11.97 Million | -5.53 Million | -2.12 Million |
| Interest Expense | 20.39 Thousand | - | - |
| Income Tax Expense | - | -160.58 Thousand | -116.54 Thousand |
| Earnings before Tax | -18 Million | -5.45 Million | -2.12 Million |
| Net Income | -18.37 Million | -5.29 Million | -2.12 Million |
| Earnings Per Share Basic | -1.76 | -0.28 | -0.11 |
| Earnings Per Share Diluted | -1.76 | -0.28 | -0.11 |
| Weighted Average Shares Outstanding | 10.45 Million | 19.08 Million | 19.08 Million |
| Weighted Average Shares Outstanding (Diluted) | 10.45 Million | 19.08 Million | 19.08 Million |
| Gross Margin | 0.67 | 0.50 | 0.76 |
| EBIT Margin | -28.25 | -17.54 | -4.60 |
| Profit Margin | -29.03 | -16.54 | -4.80 |
| EBITDA | -17.88 Million | -5.36 Million | -2.03 Million |
| Earnings Before Tax Margin | -18.91 | -17.31 | -4.80 |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 136.31 Thousand | 315.05 Thousand | 392.91 Thousand | 633.1 Thousand | 156.12 Thousand | 234.92 Thousand |
| Cost of Revenue | 41.96 Thousand | 56.04 Thousand | 116.51 Thousand | 210.39 Thousand | 50.36 Thousand | 60.96 Thousand |
| Gross Profit | 94.34 Thousand | 259.01 Thousand | 276.39 Thousand | 422.71 Thousand | 105.76 Thousand | 173.95 Thousand |
| Operating Expenses | 2.25 Million | 1.73 Million | 2.77 Million | 12.39 Million | 3.11 Million | 2.7 Million |
| Selling, General and Administrative Expenses | 1.88 Million | 1.5 Million | 2.43 Million | - | 2.62 Million | 2.31 Million |
| Research and Development Expenses | 366.01 Thousand | 235.69 Thousand | 343.7 Thousand | - | 489.26 Thousand | 394.8 Thousand |
| Other Expenses | - | - | - | -1.45 Million | - | -1.02 Million |
| Cost and Expenses | 2.29 Million | 1.79 Million | 2.89 Million | 12.6 Million | 3.16 Million | 2.77 Million |
| Operating Income | -2.15 Million | -1.48 Million | -2.5 Million | -11.97 Million | -3 Million | -2.53 Million |
| Interest Expense | 5965.00 | 3977.00 | 7618.00 | 20.39 Thousand | 7618.00 | 12.69 Thousand |
| Income Tax Expense | -17.02 Thousand | 3977.00 | 75.29 Million | 6.03 Million | -46.48 Thousand | 541.44 Thousand |
| Earnings before Tax | -2.15 Million | -1.41 Million | -2.48 Million | -18 Million | -2.96 Million | -3.07 Million |
| Net Income | -2.15 Million | -1.41 Million | -77.77 Million | -24.03 Million | -2.91 Million | -3.61 Million |
| Earnings Per Share Basic | -0.09 | -0.07 | -4.09 | - | -0.28 | -0.23 |
| Earnings Per Share Diluted | -0.09 | -0.07 | -4.09 | - | -0.28 | -0.23 |
| Weighted Average Shares Outstanding | 23.11 Million | 19.15 Million | 19.03 Million | 10.45 Million | 10.45 Million | 16.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 23.11 Million | 19.15 Million | 19.03 Million | 10.45 Million | 10.45 Million | 16.02 Million |
| Gross Margin | 0.69 | 0.82 | 0.70 | 0.67 | 0.68 | 0.74 |
| EBIT Margin | -15.82 | -4.62 | -6.29 | - | -19.12 | -15.17 |
| Profit Margin | -15.80 | -4.48 | -197.93 | -37.97 | -18.68 | -15.40 |
| EBITDA | -2.15 Million | -1.45 Million | -2.47 Million | - | -2.98 Million | -3.56 Million |
| Earnings Before Tax Margin | -15.82 | -4.70 | -6.36 | -18.91 | -19.27 | -10.79 |
MAH
AUEEF
8250
0403
PPLFY
MET-PA